[Type here]  
 
Title: REVERSING SYNCHRONIZED BRAIN CIRCUITS WITH TARGETED AUDITORY -
SOMATOSENSORY STIMULATION TO TREAT PHANTOM PERCEPTS – STAGE 2  
Brief title: Targeted auditory -somatosensory tinnitus treatment  
Protocol Number: HUM00143675  
National Clinical Trial (NCT) Identifi ed Number:  [STUDY_ID_REMOVED]  
Principal Investigator:  [INVESTIGATOR_183739], PhD  
Sponsor: National Institutes of Health (NIMH)  
Funded by :  [CONTACT_183752]1MH114244  
 
Version Number:  v.1.12 
16 February 2022  
 
 
Summary of Changes  from Previous Version:  
Affected 
Section  Summary of Revisions Made  Rationale  
1.2 Updated both schemas in Section 1.2 of 
the protocol  -  The schema on page 6 shows the 
End of Study visit occurring prior to 
the washout, but this visit happens 
after the washout, as shown in Section 1.3.  
-  The schema on page 7, in the Visit 
15-28 Time Point section, states the 
final washout is 4 weeks, but it is actually 6 weeks, as shown in Section 
1.3 and confirmed by [CONTACT_123894].  
1.1 Added an exclusion criterion  - Added “pulsating” because t his 
type of tinnitus is not what the 
NIH-FDA Phase 2 and 3 IND/IDE Clinical Trial Protocol Template    
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  ii device has been tested on with the 
animals.  
8.1 Deleted “within 30 days.”  - Give subjects more flexibility for 
when is best to begin the study with 
their schedule or if they need to wait 
on an MRI.  
6.1.2  Added “Completion of Arm [ADDRESS_216944] to be 
consecutive, an d we will allow for 12 
week s in between in order to provide 
more flexibility for subjects.”  - Give subjects flexibility to remain in 
study, if they have to miss a chunk of time due  to a family emergency, job, 
etc.  
8.1 Added section under Specific 
Procedures: Otologic examination and 
medical case history regarding mental 
health identification  -noting that if mental health issues 
are identified during screening 
process, subjects will be referred 
back to their PCP for further evaluation and/or follow -up. 
7.3 Added sentence defining missed visits and protocol deviation  -Clarifying that one missed  visit per 
6-week time period does not qualify 
a protocol deviation.  
5.5 Added section detailing remote consenting  -allows subjects to consent remotely 
to reduce unnecessary in -person 
visits  
5.1 Expanding hearing criteria -slightly expanding 
inclusion/ex clusion hearing criteria 
to include more subjects in the study  
 Expanding consenting number from 300 to 400  -allows more subjects to be 
consented to reach goal for active subjects  
NIH-FDA Phase 2 and 3 IND/IDE Clinical Trial Protocol Template    
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216945]. Stucken to refer as nee ded 
8.2 Updating adverse event reporting to match IRBMED  Updating adverse event reporting timeline from 7 days to 14 days to match IRBMED  
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  ii Table of Contents  
STATEMENT OF COMPLIANCE  ................................................................................................................ 1  
1 PROTOCOL SUMMARY  ................................................................................................................ 1  
1.1 Synopsis  ......................................................................................................................... 1  
1.2 Schema  .......................................................................................................................... 5  
1.3 Schedule of Activities (SoA)  ................................................................................................ 8  
2 INTRODUCTION  ......................................................................................................................... 8  
2.1 Study Rationale  ................................................................................................................ 8  
2.2 Background  ..................................................................................................................... 8  
2.3 Risk/Benefit Assessment  .................................................................................................. 10 
2.3.1 Known Potential Risks  ..................................................................................... 10 
2.3.2 Known Potential Benefits  ................................................................................ 11 
2.3.3 Assessment of Potential Risks and Benefits  ......................................................... 11 
3 OBJECTIVES AND ENDPOINTS  .................................................................................................... 11 
4 STUDY DESIGN  ........................................................................................................................ 14 
4.1 Overall Design  ............................................................................................................... 14 
4.2 Scientific Rationale for Study Design  .................................................................................. 15 
4.3 Justification for Dose  ....................................................................................................... 15 
4.4 End of Study Definition  .................................................................................................... 15 
5 STUDY POPULATION  ................................................................................................................ 15 
5.1 Inclusion Criteria  ............................................................................................................ 15 
5.2 Exclusion Criteria  ............................................................................................................ 16 
5.3 Lifestyle Considerations  ................................................................................................... 17 
5.4 Screen Failures ............................................................................................................... 17 
5.5 Strategies for Recruitment and Retention  ........................................................................... 17 
6 STUDY INTERVENTION  .............................................................................................................. 18 
6.1 Study Intervention(s) Administration  ................................................................................. 18 
6.1.1 Study Intervention Description  ......................................................................... 18 
6.1.2 Dosing and Administration ............................................................................... 22 
6.2 Preparation/Handling/Storage/Accountability  ..................................................................... [ADDRESS_216946] Storage and Stability  ........................................................................... 23 
6.2.4 Preparation  .................................................................................................. 23 
6.3 Measures to Minimize Bias: Randomization and Blinding  ....................................................... 24 
6.4 Study Intervention Compliance  ......................................................................................... 24 
6.5 Concomitant Therapy  ...................................................................................................... 24 
6.5.1 Rescue Medicine  ............................................................................................ 24 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL  .......... 25 
  
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017  iii 7.1 Discontinuation of Study Intervention  ................................................................................ 25 
7.2 Participant Discontinuation/Withdrawal from the Study  ........................................................ [ADDRESS_216947] to Follow -Up ........................................................................................................... 26 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 26 
8.1 Efficacy Assessments  ....................................................................................................... 26 
8.2 Safety and Other Assessments  .......................................................................................... 28 
8.3 Adverse Events and Serious Adverse Events  ........................................................................ 30 
8.3.1 Definition of Adverse Events (AE)  ...................................................................... 30 
8.3.2 Definition of Serio us Adverse Events (SAE)  .......................................................... [ADDRESS_216948]  ................................................................................ 34 
8.3.9 Reporting of Pregnancy  ................................................................................... 34 
8.4 Unanticipated Problems  .................................................................................................. 34 
8.4.1 Definition of Unanticipated Problems (UP) .......................................................... 34 
8.4.2 Unanticipated Problem Reporting  ..................................................................... 34 
8.4.3 Reporting Unanticipated Problems to Participants  ............................................... 35 
9 STATISTICAL CONSIDERATIONS  .................................................................................................. 35 
9.1 Statistical Hypotheses  ..................................................................................................... 35 
9.2 Sample Size Determination  .............................................................................................. 36 
9.3 Populations for Analyses  .................................................................................................. 36 
9.4 Statistical Analyses  ......................................................................................................... 37 
9.4.1 General Approach  ............................................. Error! Bookmark not defined.  
9.4.2 Analysis of the Primary Efficacy Endpoint(s)  ........................................................ 37 
9.4.3 Analysis of the Secondary Endpoint(s)  ................................................................ 37 
9.4.4 Safety Analyses .............................................................................................. 38 
9.4.5 Baseline Descriptive Statistics ........................................................................... 38 
9.4.6 Planned Interim Analyses  ................................................................................ 38 
9.4.7 Sub-Group Analyses  ....................................................................................... 38 
9.4.8 Tabulation of Individual participant Data  ............................................................ 38 
9.4.9 Exploratory Analyses  ...................................................................................... 38 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ............................................ 38 
10.1 Regulatory, Ethical, and Study Oversight Considerations  ........................................................ 38 
10.1.1  Informed Consent Process  ............................................................................... 38 
10.1.2  Study Discontinuation and Closure  .................................................................... 39 
10.1.3  Confidentiality and Privacy  .............................................................................. 39 
  
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216949] Policy  ................................................................................. 43 
10.2 Additional Considerations  ................................................................................................ 43 
10.3 Abbreviations  ................................................................................................................ 44 
10.4 Protocol Amendment History  ........................................................................................... 45 
11 REFERENCES  ........................................................................................................................... 47 
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216950] ( IRB), except where necessary to eliminate  
an immediate hazard(s) to the trial participants.   
The protocol, informed consent form(s), recruitment materials, and all participant 
materials will be submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by [CONTACT_3484].  All changes to the consent form will be IRB approved; a determination will be made  regarding whether  a new consent needs to be 
obtained from participants who provided consent, using a previously  approved consent 
form. 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  
REVERSING SYNCHRONIZED BRAIN CIRCUITS WITH TARGETED AUDITORY -SOMATOSENSORY STIMULATION TO TREAT 
PHANTOM PERCEPTS – STAGE 2  
 
Study Des cription : This study will assess the effectiveness of a bimodal auditory -
somatosensory stimulation protocol in reducing the tinnitus 
loudness and life -impact in adults with tinnitus.  
Objectives:  
 
 Primary Objective:  to reduce tinnitus loudness and life impact.   
 Secondary Objectives: to alter the tinnitus spectrum minimum 
masking level  
Endpoint s:  
Primary Endpoint s:  
1) Tinnitus Loudness: (TinnTester  Interactive Software)   
2) Tinnitus Functional Index  (TFI) questionnaire  
3) Tinnitus Handicap Inventory ( THI)  
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   2 Secondary Endpoints:  
1)Tinnitus bandwidth/spectrum (TinnTester Interactive Software)  
2) Tinnitus Hearing Survey (THS)  
3) Minimum Masking Levels (MML)  
 
 
  
Study Population:  
Inclusion and Exclusion Criteria  
Inclusion:  400 male or female, adult  (18 years of age and 
older)  subjects will be consented  with a goal of including up to [ADDRESS_216951] be 18 years of age or older.  
2. A score of >[ADDRESS_216952] report constant, subjective, preferably unilateral tinnitus without any active external or middle ear pathology.   
4. No greater than a moderate hearing loss at the tinnitus frequencies ( ≤55 dB HL)  and no greater than a moderate 
hearing loss ( ≤50 dB HL ) from 125 – [ADDRESS_216953] 6 months.  Tinnitus should be 
bothersome.  
7. Absence of retrocochlear pathology/ VIIIth nerve lesion  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216954] six months  or participation in the UM stage 1 
clinical trial. 
9. Resides within 100 miles of the study site.  
 
Exclusion:  
1. Anyone not meeting the above inclusion criteria, and in 
addition:  
2. Diagnosis of Meniere’s disease  
3. Dianosis of Semicircular Canal Dehiscence  
4. Unilateral or bilateral cochlear implant recipi[INVESTIGATOR_840]  
5. Diagnosis of acoustic neuroma  
6. Reports their tinnitus is pulsating  
7. Evidence of retrocochlear disease  
8. Patients with any indwelling electronic stimulation 
devices  
9. Current or previous use of any acoustic hearing aid or over the counter personal sound amplification product (PSAP) in the last [ADDRESS_216955] 6 months: high dose aspi[INVESTIGATOR_248]  
(>325mg/day) , high dose NSAIDs (ibuprofen, Motrin, 
Celebrex)  (>800mg/day), narcotics (any opi[INVESTIGATOR_2438]), lithium, 
clonazepam, oxazepam, cholinergic medications (anti-dementia medications), anti -depressant medications 
(serotonin specifi c reuptake inhibitors; SSRIs, tri- cyclic 
anti-depressants; TCAs); anti -seizure/convulsant 
medications (Depakote), anti- psychotic medications 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   4 (Haldol, Seroquel), Ototoxic medications , other 
chemotherapy agents , benzodiazepi[INVESTIGATOR_1651], and central 
nervous system stimulants . 
11. Current diagnoses of any of the following: obsessive 
compulsive disorder (OCD), schizophrenia, bipolar 
disorder, extreme generalized anxiety disorder, 
drug/alcohol dependence.  
12. Pregnant or nursing.  
Participant’s eligibility will be assessed at an initial examination 
conducted by [CONTACT_183753], 
audiometry, tinnitus modulation checklist, case history 
questionnaire, and the Tinnitus Functional Index (TFI) questionnaire.  
 
 
Phase:   
Phase I/II  
Description of 
Sites /Facilities  
Enrolling Participants:  . 
One site – University of Michigan Kresge Hearing Research Institute    
Description of Study 
Intervention :  
Bimodal a uditory -somatosensory  (electrical)  stimulation will be 
delivered to subjects using  specially -fabricated programmable 
device s by [CONTACT_46670]2being inc.  that adhere to FDA regulations for De -novo 
devices with non- significant risk  (as per pre -submission feedback 
from FDA) .  The devices will be programmed in the lab by [CONTACT_20229], 
and the somatosensory and auditory stimuli will be limited by [CONTACT_183754].  
The auditory stimulus , presented through a calibrated earphone,  
will simulate the tinnitus as estimated above at the tinnitus 
frequency or frequencies. The intensity of the auditory stimulus will 
be based on the  presentation levels  in the previous clinical trial that 
were found to be effective (originally based on pre clinical data) . The 
auditory stimulus level will be based on subjects’ individual hearing 
and tinnitus profile, and will be restricted to their comfort range. The durations and timing of the auditory and somatosensory  
(electrical)  stimulation will use prec linical study determined stimulus  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   5 timing and durations of stimulation ( Marks et al, 2018, STM ). The 
intensity of the electrical stimulation will be adjusted to be just 
below that which elicits mild muscle contractions.  Somatosensory 
stimulation will be delivered by [CONTACT_183755], the juncture of the 
temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by [CONTACT_183756].  If the modulation alters tinnitus loudness or 
pi[INVESTIGATOR_23025], the position that causes reduction will be the position of choice. Subjects will be able to feel a slight tingling with the onset of 
the electrical stimulation, which usually fades away after a  few 
minutes.  
To mitigate potential placebo effects, subjects will receive both a 
sham treatment and an active treatment.  The subjects will be blinded to which treatment they are receiving.  Subjects will be told 
that they may receive different treatment protocols, some of which are expected to be ineffective. While subjects will be informed that 
they will receive both the active and the sham treatment, they will 
not be told which treatment they are receiving.  As the sham 
treatment is using the same device as the active treatment, there 
will be no additional risks to the subject.   
Treatment durations: Daily, 30 - 60 minutes. Devices will 
programmed to take home for 30 -60 minutes per day for 6 weeks  
for each arm of the study (treatment and sham).  
 
Study Duration:  4 years  
Participant Duration:  10 months  
 
 
  
 
    
  
  
1.2 SCHEMA  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   6  
 
 
 
 
  
12 weeks  
6 weeks  6 weeks  6 weeks  6 weeks  Total N=400   Obtain informed consent. Screen potential participants  by [CONTACT_117473]; obtain history, document.  
Randomization  
Baseline  
Sham  Sham  Treatment  Treatment  
End of Study  
Follow Up  
Washout  Washout  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   7 Prior to  
Enrollment  
      
 
   Visit 1 -2 
Time Point  
   Home use  
Time Point  
  Visit s 3-14 
Weekly   
   Visit 15-28 
Time Point  
    Visit 29  
Time Point  
  
  Perform baseline assessments.  
Audiogram, ENT exam; tinnitus loudness, spectrum, TFI TH  questionnaires to be see 
Section 1.3, Schedule of Activities > 
Train on device use, take home device.  
At end of washout (6 weeks), then groups switch treatment (treatment to sham or sham 
to treatment) for another 6 weeks with weekly assessments, followed by [CONTACT_183757] 
6 weeks.  Follow -up assessment s of study endpoints weekly for 6 weeks treatment and 6 weeks 
washout ( refer to Section 1.3, Schedule of Activities)  
 
Final Assessments  
Section 1.3, Schedule of Activities  
And 12 week Follow -Up  
Arm 2  
N=25  Arm 1  
N=25 
 
 
Daily (morning) 30 -60 min for 6 weeks  Randomize  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   8 1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
 
 
 
[ADDRESS_216956] often 
the result of extreme noise exposure from either a single impulse noise or the accumulation of noise exposure; head and neck injury is the second leading complaint. In fact, lumbosacral or 
cervical strain account for 23% of service -connected disabilities for Iraq and Afghanistan 
veterans as of July 2009. In addition to factors that cause hearing loss, such as noise over -
exposure, tinnitus can occur as a result of temporal -mandibular joint disorder, or somatic 
insults, including lumbosacral or cervical strain. Tinnitus is on the rise in young people under 
the age of 20 because of the increased use of high -volume personal music players .  
The majority of tinnitus patients can modify their tinnitus by [CONTACT_183758], such as in jaw clenching while many can attribute their tinnitus onset to a somatic insult in the head and neck region (Levine, 1999a, Levine, 1999b, Abel and Levine, 2004). Somatic manipulations of the head and neck can modulate or induce a tinnitus percept, even in people who do not have tinnitus. Some examples of this include clenching of the jaw or neck muscles. These maneuvers can modulate the tinnitus percept in up to 80% of subjects while light cutaneous pressure over the right scapula can induce a clicking tinnitus percept. Thus, while tinnitus has long been considered an exclusive disorder of the auditory system, accumulating evidence suggests that it is an expression of neural plasticity encompassing 
reactions of multisensory neurons to changes in the neural signaling environment due to 
changes in auditory input.  
 
2.[ADDRESS_216957] auditory brainstem nucleus, the 
cochlear nucleus (CN), suggests that tinnitus may be triggered by [CONTACT_183759] -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   9 CN neurons by [CONTACT_183760], 
especially after noise damage (Shore et al., 2008) as well as head and neck trauma. Indeed, 
increased spontaneous and sound- driven firing rates in the dorsal cochlear nucleus (DCN) have 
been shown to be physiological correlates of tinnitus (Brozoski et al., 2002, Shore et al., 2008, Dehmel et al., 2012b). Our work over the past several years has provided strong support for 
somatosensory neurons from the head and neck region being involved in the generation and maintenance of tinnitus ( Zeng et al., 2009, Dehmel et al., 2012b, Zeng et al., 2012).  
Preclinical work in our lab has shown that tinnitus is generated by [CONTACT_183761] a brainstem station, the dorsal cochlear nucleus.  Here, principle neurons become hyperactive after tinnitus 
induction in an animal model.  One important mechanism that regulates neuronal firing 
properties is spi[INVESTIGATOR_2531] -timing -dependent plasticity (STDP), the up- or down -regulation of synaptic 
strength based on the order and timing of pre - and post -synaptic activity. Spi[INVESTIGATOR_2531] -timing -
dependent plasticity has been shown in the parallel fiber portion of the dorsal CN (DCN) circuit in vitro (Tzounopoulos et al. , 2004) and has been confirmed in vivo in our laboratory by 
[CONTACT_183762] -timing dependent synaptic plasticity. St imulus timing dependent 
plasticity  (StDP)  is the macroscopic correlate of STDP and has been shown to be a mechanism 
underlying persistent or lasting bimodal integration (Koehler and Shore, 2013a). This finding 
could have important, far -reaching implications for treating tinnitus, such as auditory -
somatosensory training and with surface or deep brain stimulation, both of which would be more effective if operating through synaptic plasticity.  
 
Thus, here we utilize STDP to instigate long term suppression in DCN neurons. Our studies have 
shown that particular sequences and intervals between somatosensory and auditory stimuli 
produce either enhancement or suppression (Koehler and Shore, 2013b). In our previous studies in animals we replicated this res ult using trans -cutaneous stimulation (Martel et al., 
2014). The tonal quality of tinnitus suggests that hyperactive neurons are located in tonotopic regions similar to the tinnitus frequency. Thus, in order to treat tinnitus, hyperactive neurons in 
CN reg ions tonotopi[INVESTIGATOR_183740]. This should 
reduce or eliminate the phantom perception of sound. To ensure that this suppression is long -
term, STDP based suppression in those neurons will be accomplished by [CONTACT_183763] -
specific auditory stimuli (i.e. close to the tinnitus frequency) with somatosensory stimuli with 
precise timing intervals. For more complex tinnitus, more complex auditory stimuli will be used 
to suppress firing rates across multiple regions.  Somatosensory stimulation is achieved by 
[CONTACT_183764], which contain the neurons 
that send their axons to the CN.  
The degree of hyperactivity and tinnitus can be modulated though auditory -somatosenso ry 
(bimodal) stimulation with specially -timed intervals that cause long term depression in the 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216958] year (Marks, Martel et al. 
2018) .  This stage 2 trial will replicate the previous trial but using more subjects , adding 
outcome measures,  and increasing treatment and washout period durations. 
 
2.3 RISK/BENEFIT ASSESSMENT   
 
2.3.1  K NOWN  POTENTIAL RISKS  
The known or expected risks are:  
Audiometric testing and tinnitus matching is performed routinely in audiology centers with no 
associated risks.   
The device was  custom manufactured for this study. It generates sound and somatosensory 
stimulation. There are software and hardware limiters in place to ensure the device never outputs any unsafe somatosensory or sound stimulation.  We will also make individualized 
adjustments in the lab to ensure both the sound and somatosensory stimulation are also at 
comfortable levels for you. Because of the limits in place, you will be unable to make unsafe adjustments to the sound and somatosensory stimulation.  This study is to test the 
effectiveness of the device.  
All research has the potential risk of confidentiality breach. The investigators conducting  the 
research have put the following mechanisms in place to protect confidentiality: all test results 
are de -identified. Information is also stored in password protected encrypted files or locked in a 
cabinet accessible only by [CONTACT_473].  
Based on  the s tudy protocol and stimuli used,  it is not anticipated that subjects would 
experience different or more adverse risks when tested in the treatment  vs. sham arms of the 
study. The sham treatment will consist of stimuli for which there is evidence from animal 
studies to suggest that it will not cause improvement or worsening of their tinnitus and will 
have no other side effects.  
As with any research study, there may be additional risks that are unknown or unexpected.  
While unlikely, it is possible that tinnitus may become louder or more noticeable during the 
trial.  
 
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   11 2.3.2  KNOWN POTENTIAL BENEFITS  
There may be no benefit to participants as a results of using the device. Alternatively, subjects 
may experience a decrease in tinnitus loudness or may be less both ered by [CONTACT_183765].   
 
2.3.3  ASSE SSMENT OF POTENTIAL R ISKS AND BENEFITS  
The study proposes to use a completely non -invasive device in order to  alleviate symptoms of a 
condition (i.e., tinnitus) that affects millions of people worldwide.  There is currently no 
consistent, effective treatment for tinnitus. An initial phase of this study (double -blinded 
crossover) demonstrated that when undergoing the active treatment, on average, participants (N=20) experienced a statistically significant reduction in their tinnitus loudness.  Additionally, they reported their tinnitus to be less bothersome. Therefore, the benefits far outweigh the risks.  
 The funding institution has deemed this clinical trial as “greater than minimal risk” because it does include a placebo arm.  Please refer to further documentation from the program officer (email) indicating this risk level following determination of NIMH.  
  
3 OBJECTIVES AND ENDPOINTS  
 
3.1 PRIMARY MEASURES  
1) Tinnitus loudness:  Measurements by [CONTACT_183766] (McMaster 
University, supplied by [INVESTIGATOR_124]. Larry Roberts) are completed by [CONTACT_183767] a soundproof booth. To assess loudness in this procedure, subjects adjust the level of each of 11 sounds differing in center frequency to match the level 
of their tinnitus. This gives a measure of loudness in sound pressure level ( SPL) for 
each subject (loudness matching method). The subjects then  rate each sound for the 
similarity of its frequency to the frequency of their tinnitus. This gives the tinnitus frequency spectrum for each subject. Data are recorded automatically by [CONTACT_183768]. This software package has been used extensively by [CONTACT_183769] ( Roberts et al, 2008). The TinnTester sounds will be 
delivered by [CONTACT_183770]. The devices have  hardware 
limits on the sound pressure levels so that they are presented at safe levels ( lower 
than 60 dB SL (above threshold).  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   12 2) Tinnitus Functional Index (TFI): The 25 item version of the TFI determines severity 
of tinnitus on a 100 point numeric scale (scores above 17 indicate the patient’s 
tinnitus is a problem) based on patients’ responses to [ADDRESS_216959] reliability and internal consistency in New Zealand and the [LOCATION_006].  
3) Tinnitus Handicap Inventory (THI): A 25 item questionnaire which assesses subjective impacts of tinnitus related to quality of life on a 100 point  numeric scale. 
Scores 17 points or higher are considered bothersome tinnitus.  We are including this 
measure as several other studies use it so it is a point of comparison.  
3.2 SECONDARY MEASURES 
 
1) Tinnitus bandwidth /spectrum : Near its start the TinnTester software asks 
subjects to indicate which of three sounds best resembles their tinnitus; 5 kHz pure tone (“tonal” tinnitus), a narrow band noise centered at 5 kHz (±5% of 
CF, BPN5 masker, “ringing” tinnitus), or a wider band of noise centered at 5 
kHz (±15% of CF, BPN15 masker, “hissing” tinnitus). We will relate treatment outcomes to tinnitus bandwidth by [CONTACT_183771]. We will also be able to determine whether the treatment alters bandwidth.  
2) Minimum Masking Level (MM L): Subjects adjust the level of the 5 kHz 
BPN15 sound until they can no longer hear their tinnitus. MML may prove sensitive to the bimodal treatment procedure. MML should be reduced, if 
tinnitus assessed by [CONTACT_183772]. However, even  when 
tinnitus loudness is reduced, there are subjects for whom tinnitus cannot be 
masked.  
3) Tinnitus Hearing Survey: A brief nine question survey which determines 
self-perceived handicap due to tinnitus, hearing loss, and hyperacusis . This 
questionnaire differs from the two primary questionnaires in that it qualifies any perceived handicap due to hearing loss and/or sound sensitivity (hyperacusis ).  
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   13  
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
Primary    
1) Objective Tinnitus loudness  
(TinnTester)   
 
      2) Tinnitus F unctional Index  
      
3) Tinnitus Handicap Index  
 
  1) End of 1st arm 
2) End of first washout  
3) End of 2nd arm 
4) End of second washout  
    1) End of 1
st arm 
2) End of first washout  
3) End of 2nd arm 
4) End of second washout  
   1) End of 1
st arm 
2) End of first washout  
3) End of 2nd arm 
4) End of second washout  
 To determine how 
use of device affects objective tinnitus loudness before and after the treatment and sham arms of the study.  
 To determine how use of device affects the tinnitus and quality of life before and after the treatment and sham arms of the study  
 
To determine how use of device affects the  tinnitus and 
quality of life before and after the treatment and sham 
arms of the study  
Secondary    
1) Tinnitus bandwidth /spectrum  
(TinnTester)  
        2) Minimum Masking Level 
(MML)  
 1) End of 1st arm 
2) End of first washout  
3) End of 2nd arm 
4) End of second washout  
      1) End of 1
st arm 
2) End of first washout  
3) End of 2nd arm To determine how 
use of the device may or may not change the perceived frequency (spectra) of tinnitus following the treatment or sham arms . 
  To determine if the MML for a 5kHz tone 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   14 OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINT S 
 
 
  3) Tinnitus Hearing Survey  4) End of second washout  
   1) End of 1
st arm 
2) End of first washout  
3) End of 2nd arm 
4) End of second washout  
 is reduced in the 
active treatment arm  
   
To determine if the active treatment has an effect or interaction with perceived handicap due to hearing loss and sound level 
toleranc e 
   
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 Aims/Hypotheses:  
Note: Aim 1 of the grant is to be performed in ANIMAL subjects only. However, Aim  2 of the 
grant is to be carried out in human subjects and therefore the design of Aim 2 is somewhat dependent on the results of Aim 1.  For information purposes only, both are described below:  
Specific Aim 1: Determine precise parameters/dosages for modul ating multisensory plasticity 
in fusiform cells (FCs) and cartwheel cells (CWCs) in normal and pathological (tinnitus) circuitry in guinea pi[INVESTIGATOR_14107] . Hypothesis 1: Presenting bimodal AN -SS stimuli with optimal 
parameters to guinea pi[INVESTIGATOR_183741].  
Specific Aim 2: Test parameters/dosages determined in Specific Aim 1, for modulation of multisensory plasticity in human subjects with changes in tinnitus severity as the outcome measure. Hypothesis 2: AN -SS stimuli with optimal dosage/parameters (based on the results of 
Specific Aim 1), will effectively modulate DCN circuitry to reduce tinnitus in humans. 
Exper iment 2a: Using a double -blind cross -over model, we will use a bimodal AN -SS paradigm 
with optimal stimulus parameters based on the results of Specific Aim 1 to asse ss changes in 
subjects’ tinnitus perception. Modulations in tinnitus perception will be ass essed using 
objective loudness matching and subjective measures (standard questionnaires) in response to 
active and sham bimodal stimuli. Neural circuitry changes will be assessed by [CONTACT_183773]’ tinnitus. It is anticipated that chosen bimodal intervals and durations of treatment (dose) will reduce the abnormal percepts. Experiment 2b: Subjects will 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216960] on tinnitus will be assessed as above  
Phase:  P hase I/II  
Type of design:  Double -blinded, cross -over design.  There will be two treatment ar ms 
(treatment and sham).  All subjects will participate in both arms of the study. This is a single -site 
study.  Total duration of the study for each subject will be [ADDRESS_216961] (Dobie 1999) .  Therefore, is important to include a placebo arm in order to truly evaluate 
the efficacy of the device and treatment.  It is also important that both the subject and the 
administrator (all study team members) are also blinded to the enrollment and assignment of the subjects for the same reasons.   The placebo st imulus is an auditory stimulus which is benign 
and shown in the first trial to have no effect  (Marks et al, Science Translational Medicine, 
January, 2018 , HUM00088432).   
 
4.[ADDRESS_216962] ( preclinical experiments) as stated 
above.   
   
4.[ADDRESS_216963] scheduled procedure shown in the S chedule of 
Activities (SoA), Section 1.[ADDRESS_216964] meet all of the following 
criteria:  
 
1. Must be 18 years of age or older.  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   16 2. A score of >[ADDRESS_216965] report constant, subjective, preferably unilateral tinnitus without any active external or middle ear pathology.   
4. No greater than a moderate hearing loss at the tinnitus frequencies ( ≤55 dB 
HL) and no greater than moderate hearing loss ( ≤50 dB HL ) from 125 – [ADDRESS_216966] 6 months.  Tinnitus should be bothersome.  
7. Absence of retrocochlear pathology/ VIIIth nerve lesion  
8. No participatio n in a tinnitus treatment regimen within the past six months  
and no participation in Stage 1 trial. 
9. Resides within 100 miles of study site.  
 
5.2 EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from participation in this 
study:  
1. Anyone not meeting the above inclusion criteria, and in addition:  
2. Diagnosis of Meniere’s disease  
3. Diagnosis of Semicircular Canal Dehiscence.  
4. Unilateral or bilateral cochlear implant recipi[INVESTIGATOR_840]  
5. Diagnosis of acoustic neuroma  
6. Evidence of retrocochlear disease  
7. Patients with any indwelling electronic stimulation devices  
8. Current of previous use of any acoustic hearing aid or over -the-counter 
personal sound amplification  product (PSAP) in the last [ADDRESS_216967] 6 
months: high dose aspi[INVESTIGATOR_248]  (>325mg/day), high dose NSAIDs (ibupro fen, 
Motrin, Celebrex)  (>800mg/day) , narcotics (any opi[INVESTIGATOR_2438]), lithium, 
clonazepam, oxazepam, cholinergic medications (anti- dementia 
medications ), anti- depressant medications (serotonin specific reuptake 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   17 inhibitors; SSRIs, tri- cyclic anti -depressants; TCAs); anti seizure/convulsant 
medications (Depakote), anti- psychotic medications (Haldol, Seroquel), 
Ototoxic medications, other chemotherapy agent s, central nervous system 
stimulants, and benzodiazepi[INVESTIGATOR_1651].  
10. Current diagnoses of any of the following: obsessive compulsive disorder 
(OCD), schizophrenia, bipolar disorder, extreme generalized anxiety disorder, drug/alcohol dependence.  
11. Pregnant or Nursing.  
5.3 LIFESTYLE CONSIDERATIONS  
 
During this study , participants are asked to:  
• Refrain from participation in any other tinnitus treatment  
• Report any changes in health status   
• Report any changes in prescribed or over- the-counter medications  
 
 
5.4 SCREEN FAILU RES 
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently randomly assigned to the study intervention or entered in the study. A 
minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants , to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
 
Individuals  w
 ho do not meet the criteria for participation in this trial (screen failure) because of 
a recent participation on another tinnitus treatment regimen may be rescreened  once the 
observed period of time as passed as stated in the protocol . Rescreened participants should be 
assigned the same participant number as for the initial screening. 
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
General procedures:  
Study team members will recruit patients from patient populations seen in the otology and 
audiology clinics at UMHS, as well as those who have contact[CONTACT_183774]. Shore or other study team members to report having tinnitus.  Once they have contact[INVESTIGATOR_530] a study team member, the y will 
receive an automatic reply which will be sent using the Mail Chimp email automation platform.  Please see additional documentation for Mail Chimp platform security information (Attachment A) and an email script (Attachment B) that will be sent to po tential participants.  Within the 
email script, potential participants will be directed to the clinical study website which will 
appear on the umhealthresearch.org website.  Participants will be asked to create an account 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216968] the study team through the website if 
they are interested in participating. Please see Attachment C for content that will be posted on umhealthresearch.org.  Once a potential participant has contact[CONTACT_183775].org website, he/she will be contact[CONTACT_426] a member of the study team via 
phone, email, or secure messaging via the umhealthresearch.org website in order to confirm that they meet the inclusion and exclusion criteria. Please see additional docume ntation for 
phone and/or email script (Attachment D). Once such information is confirmed, they will be scheduled for an initial visit to the lab at which time consenting and candidacy evaluations will 
be performed.  
 
Subjects may also sign the informed consent through the SignNow application. Subjects will meet with a staff member through HIPAA compliant Zoom videocall platform where the staff member will review the informed consent with the subject and answer any questions the subject may have prior to signing the document.  
 
The patient will have the opportunity to ask questions at all times throughout the recruitment process. All questions or concerns will be addressed by a study team member. Through purposeful sampling, we will attempt to include a diverse set of respondents based on ethnic, socioeconomic, and educational backgrounds.    
 Target study sample size: We will enroll 4 00 subjects in order to assign up to 100 subjects to 2 
treatme nt arms. We anticipate testing 34 subjects per year in order to meet this recruitment 
goal. There is one recruiting site (University of Michigan).  
 Subjects will be provided compensation for parking at each visit.  
 
6 STUDY INTERVENTION 
 
6.1 STUDY INTERVENTION (S) A DMINISTRATION  
 
6.1.1  S TUDY INTERVENTION  DESCRIPTION  
Describe the study intervention(s) and control product. Product information can usually be 
obtained from  the: 
• The investigational devices for providing the stimulation protocols have been designed 
by [CONTACT_183776]2being , LLC .  The device provides 
acoustic and electrical stimulation at levels deemed safe by O SHA,  ISO and ANSI.         
• The device is labeled “for investigational use only ” 
• Final labeling for a marketed devic e will be obtained after FDA final review after 
completion of the trial. In2being , LLC  will incorporate any changes to the labeling that 
are suggested.  
•  A pre -submission has been reviewed already by [CONTACT_183777], non- significant risk.  
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   19 In addition: 
• FDA and the IRB consider our device class 2 de novo, thus we do not require an IDE to 
run the clinical trial,  stage 2.  
• The study intervention is not yet commercially available . Since the stage 1 clinical trial 
that has been completed, we are hiring In2being to upgrade the devices so that the next generation is FDA compliant.  
• If conducting a study with a device, the following information should be included:  
o Device size(s): Less than 3”/2”/7”  
o Device model(s) : Gen 2  
o Description of each component :  
 CPU 
 SD card for data storage  
 power supply  
 rechargeable lithium ion batteries  
 electrical stimulator  
 sound stimula tor 
 earphones  
 stimulating pads   
o Device settings and programming:  
 See Figure 1 for all device tunable parameters  
 Auditory SPL below 95 dB SLP  
 Current less than 3 mA (see Figure 1) 
 Misapplication of electrodes is detected by [CONTACT_183778].   
 Device has only two settings (on/off), limiting subject errors.  
o Duration of stimulation (30 -60 min/day).  
o Once per day  
o Current levels with known potentiometer values  and Maximum  SPL are shown in 
Fig. 2 
• Figure 1: Device Tunable Parameters. Each indicated parameter is regulated by [CONTACT_133238]. Current level, audio intensity and frequency content are altered on an individualized basis for the treatment; all other parameters remain fixed.  
•  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   20 •   0 20 40 60 80 100 120 140 160 180 200-1.5-1-0.500.511.5Figure of Protocol Trial
Time of Single Trial (ms)Stimulus Amplitude
  
Audio Signal
Electrical SignalAudio Duration
Audio OnsetAudio IntensityTrial Duration and Number of Repetitions
Electrical Intensity
Pulse CountPulse DurationPu
lse Interval
Frequency ContentOnset 
Delay
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   21 • Figure 2. Calibration Data. Stimuli are calibrated prior to device use. A)  Each device 
features an internal self -calibration for the electrical stimulator. This check is run every 
trial to ensure appropriate treatment stimulation. This fe ature also checks for open and 
short circuits, which indicate improper electrode placement. For a given potentiometer 
value (x -axis), the device output current (right y -axis) and regulated voltage (left y -axis) 
are shown. B) Device ear phones are matched to a device and calibrated using a 
standard microphone. Dashed line shows earphone output without limiter installed, solid with limiter.  
•  
•  
•   
0 
 200 
 400 
 600 
 800 
 1000  
 1200  
Potentiometer Value (index)  
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
0 
0.5 
1 
2 
2.5 
3 
Current (mA)  
Device electrical stimulation values  
1.5 
Voltage (V)  
0 
 2 
 4 
 6 
 8 
 10 
 12 
 14 
 16 
Freq (kHz)  
75 
80 
85 
90 
95 
100 
105 
110 
115 
120 
Intensity (dB SPL)  
   
Earphone Calibration  
without limiter  
with limiter  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216969] their tinnitus spectrum assessed with the T inn Tester  protocol  (L. Roberts 
et al, 2008).  This spectrum is digitized and programmed into the device as the signal to be 
delivered to the subject.  The amplitude is limited to [ADDRESS_216970] and is delivered together with 
an electrical stimulus delivered a short time after the auditory stimulus (as determined by [CONTACT_183779]).  This stimulus is presented by [CONTACT_183780].  The device limits the time of presentation to [ADDRESS_216971] been effectively trained, subjects will take the devices home to use for 
the 30 -60 min/day periods.  Once a week the primary and secondary outcomes will be tested 
along with any review or questions that the subjects need to be answered. Subjects are aske d 
to use the device at the same time every day but If subjects miss a treatment they are 
instructed to use it at another time rather than miss that treatment.  
   
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
 
6.2.1  A CQUISITION AND ACCOUNTABILITY  
In2being will pro vide a unique identifier for each device .  The study team members will 
program the devices based on individuals’ audiograms and tinnitus spectra and will show the 
subjects how to use the devices to implement the treatments.  Devices will be returned to study team members following subject partic ipation.  Devices will be reprogrammed for 
subsequent subjects.    
 
6.2.2  FO
RMULATION, APPEARANCE, PACKAGING, AND LABELING  
See Figure 3. 
Figure 3. Generation 1 Device Pi[INVESTIGATOR_499]. Generation 2 devices, to be tested in this study, will not 
be larger than the current designs, and will feature upgrades to ensure FDA approval.  
Device dimensions: less than 2” x 5 “ x 8”  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216972] (neck skin or face skin) with 
alcohol- based  wipes prior to electrode placement.  
    

Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   24 6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
Subjects are randomly assigned to group 1 (active first, then sham) or group 2 (sham first, then 
active) using Matlab’s randsample  command with a predetermined, fixed, secret seed value. 
Randsample  generates random numbers using the Mersenne twister algorithm. We will enroll 
subjects in a 1:[ADDRESS_216973] is generated algorithmically, the code can be reproduced with knowledge of the secret seed value. Unblinding may occur at the end of the study or in the case 
of an SAE related to the study (worsening of tinnitus, worsening of hearing threshold). Study 
investigators that do not have contact [CONTACT_183781]. Intentional and unintentional unblinding must be reporte d to the principle investigator .  
Imperfect blinding could arise from the presence of the electrical stimulation present during active treatment. To avoid unblinding, subjects will be told that they may or may not feel 
electrical stimulation during both phases of the study. The previous study suggested that 
subjects tend to acclimate to the presence or lack of electrical stimulation during a day’s 
treatment. Subjects will be discouraged from divulging whether they can feel the electrical 
stimulus.  
No investigators are allowed to remain unblinded for the duration of the study.  All analyses that could require unblinding (SAEs, worsening of a subject’s  tinnitus/hearing) will be identified 
by [CONTACT_183782], and the investigators notified by [CONTACT_183783].  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
The devices are electronic monitoring compliant – successful daily use is registered, also detects 
and records open circuits or failures.  Primary and secondary outcomes are measured weekly 
and recorded by [CONTACT_183784].  
 
6.5 CONCOMITANT THERAPY  
NA 
 
6.5.1  RES CUE MEDICINE  
NA 
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   25 7 STUDY INTERVENTION DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION/ WITHDRAWAL  
 
7.[ADDRESS_216974], data for the TFI,  THI, and TinnTester  will be examined on a weekly basis (following 
weekly testing for each subject) for tinnitus assessments.  Additionally, audiometric criteria will be assessed at least every 6 weeks (please see schedule of events) to monitor hearing status.  Audi ometric criteria will be evaluated during the interim if a subject reports concern for a 
change in hearing ability.   This metric will be monitored by [CONTACT_71498].  If tinnitus is found to  
statistically, significantly  increase according to aggregated mean baseline , then the subject will 
not continue in the study regardless of which arm (active or sham) in which the subject is enrolled.  Furthermore, if the subject subjectively reports increase in tinnitus or worsening of hearing, without a significant change in any of the subjective or objective measures, and he/she wishes to discontinue participation in the study then he/she will withdraw from the study.  
 A subject’s participation in the study will be discontinued following b
 oth 1) an increase of 16 or 
more poin ts in TFI, and 2) an average increase of [ADDRESS_216975]’s subjective response to their tinnitus.   However, TFI can also reflect outside life stres sors unrelated to the treatment and 
could result in a subject's discontinuation for reasons unrelated to the treatment.
 
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
• Pregnancy  
• Significant study intervention non-compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best interest of the participant  
• If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
• Participant becomes unable to participate in the study on a weekly basis.  
The reason for participant discontinuation or withdrawal from the study will be recorded on the 
Case Report Form ( CRF). Subjects who sign the informed consent form and are randomized but 
do not receive the study intervention may be replaced.  Subjects who sign the informed 
consent form, and are randomized and receive the study intervention, and subsequently 
withdraw, or are withdrawn or discontinued from the study , will be replaced.  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216976] TO F OLLOW -UP 
 
A participant will becom e ineligible to continue in the study if he/she misses more than one 
visit for each of the following 6 -week time periods: Arm [ADDRESS_216977] be taken if a participa nt fails to return to the clinic for a required 
study visit:  
• The site will attempt to contact [CONTACT_62541] 1 
week  and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain if the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls, emails or portal messages).  
• Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason o f lost to follow -up. If participant 
refus es to return device, the Office of General Council and/or the UM Police department 
will be notified of device theft,  pursuant to Mich. Comp.  § 750.356(3), § 750.356a(1) , 
“Felony Theft in Michigan”.  
 
8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 EFFICACY ASSESSMENTS  
 Study Procedures:  
 General overview : All subjects will complete consenting and then a candidacy evaluation to 
determine if they meet study criteria.  Once they meet criteria, they will be scheduled for a baseline re -assessment.  Following the baseline assessment,  they will be randomly assign ed to a 
study arm (treatment or sham) and then training on how to use the device before taking it home.  They will take home the device on the same day they complete the baseline 
assessment.  Follow up assessments will take place weekly, and assessments co mpleted at the 
weekly session are noted below. Additionally, some measures will only be completed at the beginning or end of the active treatment or sham conditions and following washout of active or sham treatment.  
 Specific procedures:  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   27 1. Audiologic case history:  
a. Will be administered to each enrolled subject at the initial appointment in the 
study (candidacy evaluation) following completion of the consent form.  This 
questionnaire includes basic information regarding the patient’s audiolog ic and 
medical history. This will be administered by [CONTACT_183785].  This is not repeated at any other point in the study unless the 
patient reports a change in audiologic history.  
2.  Otologic examination and medical case history : 
a. Will be administered to each enrolled subject at the initial appointment in the 
study (candidacy evaluation) following completion of the consent form.  This questionnaire includes basic information regarding the patient’s otologic and medical history. This will be administered by a physician/otologist on the study 
team.  This is not repeated at any other point in the study unless the patient 
reports a change in otologic or medical history.  
b. If an otologic examination warrants further medical evaluation or intervention (standard of care) then an appropriate recommendation will be made by a physician study team member.  If a subject is required to seek further medical evaluation, he/she will not be able to participate in the trial until he/she has been properly evaluated and has provided test results or a letter from a physician indicating as such.  These costs are not covered by [CONTACT_1758].  
c. If mental health issues are identified during the screening process, the screening physician will refer the s ubject back to their primary care physician for further 
evaluation and/or follow -up. 
3. Tinnitus modulation checklist 
a. Will be administered to each enrolled subject at the initial appointment in the study (candidacy evaluation) following completion of the consent form.  This questionnaire involves a study team member asking the subject to perform a series of movements and then requiring that the subject subjectively report if a given movement caused a change in tinnitus.  Only subjects who are able to modulate their tinnitus with one of the somatic maneuvers will be eligible to 
participate in the study. This will be assessed at the candidacy evaluation, and then according to the Schedule of Events (Section 1.3).  
4.  Audiometric assessment : 
a.  A basic audiometric assessment will be performed at the initial appointment in 
the study (candidacy evaluation) following completion of the consent form  and 
then according to the Schedule of Events (Section 1.3) .  The basic audiometric 
assessment follows standard clinic procedures in both ears.  This includes a behavioral audiogram using air- conduction (250 -8000 Hz) and bone conduction 
(250- 4000 Hz) stimuli presented through calibrated headphones or bone 
conduction transducer, respectively.  Speech detecti on thresholds will also be 
assessed to determine reliability. This data will be assessed to determine if a subject meets eligibility criteria for hearing loss.  It will also be reassessed bi-weekly to determine if hearing thresholds worsen during each trea tment arm as 
outlined in the stoppi[INVESTIGATOR_3418].  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   28 5. TinnTester:  
a. Objective tinnitus loudness (TinnTester) : This assessment is described in Section 
3 of this document.  It will be assessed at the  baseline  evaluation, and then 
according to the Schedule of Events (Section 1.3).  
b. Objective  tinnitus bandwidth (TinnTester) : This assessment is described in 
Section 3 of this document.  It will be assessed at the baseline  evaluation, and 
then according to the Schedule of Events (Section 1.3).  
c. Sound tolerance level (TinnTester) : This assessment is described in Section 3 of 
this document.  It will be assessed at the baseline  evaluation, and then according 
to the Schedule of Events (Section 1.3).  
 
  
6. Minimum Masking Level:  
a. This assessment is described in Section 3 of th is document.  It wi ll be assessed at 
the baseline evaluation, and then according to the Schedule of Events (Section 
1.3).  
7.  Tinnitus Function Index (TFI)  
a. This assessment is described in Section 3 of this document.  It will be assessed at the candidacy evalu ation, and then according to the Schedule of Events (Section 
1.3).  
8. Tinnitus Handicap Inventory (THI)  
a. This assessment is described in Section 3 of this document.  It will be assessed at the baseline  evaluation, and then according to the Schedule of Events ( Section 
1.3).  
9. Tinnitus Hearing Survey (THS) : 
a. This assessment is described in Section 3 of this document.  It will be assessed at the baseline evaluation and then according to the Schedule of Events (Section 1.3) 
 
8.[ADDRESS_216978] clinical intervention. Subjects will be informed during the consenting process that there are alternative methods of treatment such as so und therapy that they may find beneficial, and 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216979] experience an a
dverse ev ent or worsening of symptoms. We will stop the study should 10% of subjects show a 
persistent worsening in their symptoms. A subject’s participation in the study will be discontinued following both  1) an increase of 16 or more points in TFI, and 2) an aver age 
increase of [ADDRESS_216980]’s subjective response to their tinnitus.   However, TFI can also reflect 
outside life stressors unrelated to the treatment and could result in a subject's discontinuation for reasons unrelated to the treatment.  A subject’s participation can also be discontinued even 
if the criteria above is not met, but the subject feels their tinnitus is worse.   
 T
his study does not require and will not use a Data Safety Monitoring Board (DSMB) because it 
is not a multi -site study.  However, because it is a double -blinded, cross -over study we will 
implement and an Independent Safety Monitor (ISM) for data monitoring purposes.  The ISM will be clinical research monitor of the Michigan Institute for Clinical & Health Research (MICHR) 
who can provide independent monitoring of the human data. The ISM will be responsible for overseeing and monitoring the enrollment data, safety data and data integrity.  The ISM will be 
unblinded to the intervention assignment for each subject.  The ISM will be independent of the 
investigation.  He/she will not be a collaborator, co -author, supervisor, mentor/mentee, 
research lab member, or member of the institutional department within the last three years. He/she will not have any professional or financial  conflict of interest.  
 The PI (Susan Shore, PhD) will comply with the NIMH Reportable Events policy. The intervention will continue for each subject so long as adverse events do not occur for that individual.  The ISM will monitor data and review safety data.  If adverse events related to the study (definitely related, probably related, or potentially related) do occur, they will be reported to the IRB within [ADDRESS_216981], data for the TFI, THI, 
TinnTester, and audiologic exa minations will be examined on  a weekly basis (following weekly 
testing for each subject) for tinnitus assessments to  determine if either measures indicate a 
statistically significant increase in tinnitus or decrease in hearing (in reference to the 
individual’s baseline measure).  This metric will be monitored by [CONTACT_71498].  If tinnitus is found to increase or hearing loss  worsen, then the subject will not continue in the study regardless of 
which arm (active or sham) in which the subject is enrolled.  Furthermore, if the subject subjectively reports increase in tinnitus or worsening of hearing, without a significant change  in 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   30 any of the subjective or objective measures, and he/she wishes to discontinue participation in 
the study then he/she will withdraw from the study.   The study protocol and treatment device includes transmission of both acoustic and electric (transdermal) stimulation.  For both stimulation types, stimuli are strictly controlled as to not cause harm or discomfort for the subject. For acoustic stimulation, the intensity is set at 30 dB SL (as determined by [CONTACT_423]’s pure tone average), with each sound presented for [ADDRESS_216982] (based on clinical experience and previous research trial data).  
For the electric stimulation, the electrodes are positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, C1 or C2, depending on which region modulates the tinnitus (based on the modulation maneuver checklist. Electrical stimulation levels are just below the threshold of muscular contraction (1 -3 mA) as in the animal studies, limited by [CONTACT_1130]’s comfort. This level of electric 
stimulation is typi[INVESTIGATOR_183742] a small, comfortable tinging at the stimulation site upon initial activation.  However, based on our previous research trial subjects often report that electric stimulation cannot be detected within a few minutes of initial stimulation.  This low level of electrical stimulation c auses no harm to the subject.  The sham protocol uses the 
same electrical and acoustic levels but the bimodal interval is wider than that used to induce STDP (>100 ms). Based on work in the animal, we expect that using wider bimodal intervals will cause no  harm to the subject.  
The subject will be consented by [CONTACT_183786].  Consenting will take place in the Human lab on the 2nd floor of Med. Sci. I. at the 
University of Michigan , or online via HIPAA approved Zoom videoconferencing application .  
Patients will be seated in a comfortable chair in a semi- private room and be allowed to ask 
questions regarding the study.  Tinnitus assessments will take place in a private, double -walled 
sound booth.  Fitting of the device will take place in a semi- private laboratory room.  Medical 
evaluations will be completed by [INVESTIGATOR_124]. Basura  or [CONTACT_183800] in a private examination room at the 
Otology Clinic at the University of Michigan, in the Human Lab on the [ADDRESS_216983] information secure.  All data will be collected and tracked electronically.  Data will be stored, using a secure data network system  supported by [CONTACT_183787] (MICHR).  Subjects will communicate with 
research team members by [CONTACT_14223] a secure web portal. Data will be coded, password 
protected and encrypted.   
 
 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
 
8.3.1  D EFINITION OF ADVERSE EVENTS (AE)  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216984] medical occurrence associated with the use of an 
intervention in humans, whether or not considered interventi on-related (21 CFR 312.32 (a)).  
  
8.3.2  D
EFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An adverse event ( AE) or suspected adverse reaction is considered "serious" if, in the view of 
either the investigator or sponsor, it results in any of the following outcomes: death, a life -
threatening adverse event, inpatient hospi[INVESTIGATOR_1081], 
a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or a congenital anomaly/birth defect. Important medical events that may not 
result in death, be life -threatening, or require hospi[INVESTIGATOR_708], 
based upon appropriate medical judgment, they may jeopardize the participant  and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
 
8.3.3  C LASSIFICATION OF AN ADVERSE E VENT  
 
[IP_ADDRESS]  S EVERI TY OF EVENT 
 
• Mild – Events require minimal or no treatment and do not interfere with the 
participant’s daily activities.   
• Moderate – Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic 
drug therapy or other treatment. Severe events are usually potentially life -threatening 
or incapacitating.  Of note, the term  “severe” do es not necessarily equate to “serious”.]  
 
 
[IP_ADDRESS]  R ELATIONSHIP TO STUDY INTERVENTION  
 
All adverse events ( AEs) must have their relationship to study intervention assessed by [CONTACT_12288]/her clinical judgment. The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product must always be suspect.  
 
• Related  – The AE is known to occur with the study intervention , there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship 
between the study intervention and event. Reasonable possibility means that there is 
evidence to suggest a causal relationship between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study 
intervention and event onset, or an alternate etiology has been established.  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   32  
OR 
 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to study intervention 
administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the study intervention (dechallenge) should 
be clinically plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge procedure if necessary.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence 
of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the study intervention , is 
unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
• Potentially Related – There is some evidence to sugges t a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Altho ugh an AE may rate only as “possibly 
related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate.  
• Unlikely to be related – A clinical event, including an  abnormal laboratory test result, 
whose temporal relationship to study intervention administration makes a causal 
relationship improbable (e.g., the event did not occur within a reasonable time after administration of the study intervention ) and in which o ther drugs or chemicals or 
underlying disease provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
• Not Related – The AE is completely independent of study  intervention administration, 
and/or evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiolo gy documented by [CONTACT_15370].  
  
[IP_ADDRESS]  EX
PECTEDNESS  
 The PI [INVESTIGATOR_183743] ( AE) is expected 
or unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the risk information previously described for the study 
intervention.  
8.3.4  T
IME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   33 The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the 
attention of study personnel during study visits and interviews of a study participant presenting 
for medical care, or upon  review by a study monitor.  
 All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate  case report form ( CRF). Information to be collected includes event 
description, time of onset, clinician’s ass essment of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless  of relationship. All AEs will be followed to adequate resolution.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 The PI [INVESTIGATOR_183744] 7 (for non -serious AEs) or 30 days (for SAEs) after the  last 
day of study participation.  At each study visit, the investigator will inquire about the 
occurrence of AE/SAEs since the last visit.  Events will be followed for outcome information 
until resolution or stabilization.  
  
8.3.5  A
DVERSE EVENT REPORTING  
The P I (Susan Shore, PhD) will comply with the NIMH Reportable Events policy. The intervention 
will continue for each subject so long as adverse events do not occur for that individual.  The 
ISM will monitor data and review safety data.  If adverse events  relat ed to the study (definitely 
related, probably related, or potentially related)  do occur, they will be reported to the IRB 
within [ADDRESS_216985] ( IRB) as soon as possible, 
but in no event later than [ADDRESS_216986] and shall report the results of such evaluation to the Food and Drug Administration ( FDA) 
and to all reviewing IRBs and participating investigators within 10 working days after the 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216987] as FDA requests.  
 
8.3.7  RE PORTING E VENT S TO PARTICIPANTS  
N/A 
 8.3.[ADDRESS_216988]  
N/A 
8.3.9  RE PORTING OF PREGNANCY  
N/A 
 
 
8.4 UNANTICIPATED PROBLEMS  
 
8.4.1  D EFINITION OF UNANTICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections ( O HRP) considers unanticipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol- related documents, such as the Institutional Review 
Board ( IRB)-approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
• Related or pos sibly related to participation in the research (“possibly related” means 
there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• Suggests that the research places par ticipants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously known or recognized.  
 This definition could include an unanticipated adverse device effect, any serious adverse effect on health  or safety or any life -threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a  supplementary plan or 
application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare  of subjects (21 CFR 812.3(s)).  
  
8.4.2   UN
ANTICIPATED PROBLEM REPORTING  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   35 The investigator  will report unanticipated problems ( UPs) to the reviewing Institutional Review 
Board ( IRB) and to the Data Coordinating C enter ( DCC)/l ead principal investigator ( PI). The UP  
report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB 
project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or  
outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP . 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
time line:   
 
• UPs that are s erious adverse events ( SAEs) will be reported to the IRB and to the 
DCC/study sponsor within 10 days  of the investigator becoming aware of the event.  
• Any other UP  will be reported to the IRB and to the DCC/study sponsor within 10 days of 
the investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_8706]’s written reporting procedures), t he supporting agency head (or designee), 
and the Office for Human Research Protections ( OHRP ) within 10 days of the IRB’s 
receipt of the report of th e problem from the investigator.  
 
  
8.4.3  R
EPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
N/A 
 
[ADDRESS_216989] administrators. A 
General Linear/Logistic Mixed (GLLM) effects analytic model was developed in consultation with UM statistics  department prior to our preliminary trial. GLLM is considered ideal when 
analyzing repeated measures as it treats time as a continuous variable and can account for missing data. This framework can readily adapt to subgroupi[INVESTIGATOR_183745]. GLLM 
analysis includes random and fixed effects. In this study, treatment order (active first vs sham 
first), treatment condition (active, active washout, sham, sham washout), baseline loudness, 
baseline TFI, and interaction of treatment and treatment order are treated as fixed while intercept is treated as a random effect.  All metrics are computed relative to baseline for each 
subject.  
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   36 MICHR has provide d templates, tools, and general guidance in support of activities conducted 
by [CONTACT_183788], and will continue to do so . The 
University of Michigan’s Department of Statistics Consulting for Statistics, Computing and 
Analytics Research (CSCAR) has provide d individualized support and training to our team on  
management, collec tion, and analysis of data  for phase 1 (which is identical to the second 
except in terms of subject numbers and treatment duration) . Staff are available for continued  
support in the  use of technical software, and advanced computing in research.  
 
• Primary Efficacy Endpoint(s):  
 
1) Objective Tinnitus Loudness  
2) Tinnitus Functional Index  
3) Tinnitus Handicap Index  
 
• Secondary Efficacy Endpoint(s):  
1) Tinnitus bandwidth /spectrum  
2) Minimum masking level 
3) Tinnitus Hearing Survey  
  
9.[ADDRESS_216990] by [CONTACT_183789]. With these parameters, alpha = 0.05 and beta = 0.8, we simulat ed new data sets with samples ranging 
from [ADDRESS_216991]’s data will be analyzed in one cohort. We will perform both per -protocol and 
intention- to-treat analyses. While intention- to-treat analysis is ideal, our protocol may require 
subjects to adhere to a strict schedule in order to fully realize the benefit of the treatment. Our pi[INVESTIGATOR_183746], but a longer and larger study provides more 
opportunity for non- compliant subjects. Should sensitivity analysis between the intention- to-
treat and per -protocol analyses attain significance, differences between compliant and non-
comp liant subjects will be further explored in an effort more fully understand who best can 
benefit from the bimodal protocol. Missing data and losses to follow- up will be managed using 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216992] deviations. All hypothesis -testing derived 
analyses will utilize an alpha of 0.05, beta of 0.8, and utilize two -tailed tests .  
 
9.4.1  AN ALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 For all endpoin ts (Tinnitus loudness, TFI and THI), the following approach will be utilized. All 
measures are ordinal, repeated measures. Final analysis will occur after unblinding.  
 Tinnitus loudness is measured by [CONTACT_183790] r 
tinnitus to one of 11 sounds with different center frequencies. Absolute differences are averaged relative to baseline to determine loudness. TFI and THI are questionnaires to be completed at each weekly visit. Both are measured on an interval scale.  See section 3.1 for 
more details  
 A General Linear/Logistic Mixed (GLLM) effects analytic model will be used . GLLM is considered 
ideal when analyzing repeated measures as it treats time as a continuous variable and can 
account for missing data. This framework  can readily adapt to subgroupi[INVESTIGATOR_183745]. 
GLLM analysis includes random and fixed effects. In this study, treatment order (active first vs 
sham first), treatment condition (active, active washout, sham, sham washout), baseline loudness, basel ine TFI, and interaction of treatment and treatment order are treated as fixed 
while intercept is treated as a random effect.  
 Adjustments for Type I error over the set of endpoints is unnecessary as the measures are not directly related.  
  
9.4.2  AN
ALYSIS OF THE SECONDARY ENDPOINT(S)  
 
The following analytical framework will be applied to 2ndary measures  (see section 3.2 for 
more details) . Analyses are not dependent on primary -measures. All measures are ordinal, 
repeated measures. Data will be analy zed using repeated -measures ANOVA, and shown as 
mean+/ -SEM. Normality will be assessed using Kolmogorov -Smirnoff tests, and non- parametric 
tests used for non -normally distributed data.  To assess how the secondary measures might co 
vary with the primary measures, we will use principal component analysis or linear fixed effects models.  
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216993]’s baseline.    
 
9.4.5  P LANNED INTERIM ANALYSES  
N/A 
 9.4.6  S
UB -GROUP ANALYSES 
N/A 
 9.4.7  T
ABULATION OF INDIVIDUAL PARTICIPANT DATA 
State whether individual participant  data will be listed by [CONTACT_8707].  
 
Individual data will be listed by [CONTACT_7206].  
 
9.4.8  E XPLORATORY ANALYSES 
To be determined.  
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND S TUDY OVERSIGHT CONSIDERATIONS  
 
 
10.1.1  I NFORMED CONSENT PROCESS  
 [IP_ADDRESS] C
 ONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED 
TO PARTICIPANTS  
Consent forms describing in detail the study intervention, study procedures, and risks are given 
to the participant and written documentation of informed consent is required prior to starting 
intervention/administering study intervention.   
 
[IP_ADDRESS] C ONSENT PROCEDURES AND DOCUMENTATION  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation.  Consent forms will be 
Institutional Review Board ( IRB)-approved and the participant will be asked to read and review 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   39 the document. The investigator will explain the res earch study to the participant and answer 
any questions that may arise. A verbal explanation will be provided in terms suited to the 
participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research p articipants.  Participants will have the opportunity to carefully 
review the written consent form and ask questions prior to signing.  The participants should 
have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done specifically for the study. Participants must be informed that 
participation is voluntary and that they may withdraw from the study at an y time, without 
prejudice.  A copy of the informed consent document will be given to the participants for their 
records. The informed consent process will be conducted and documented in the source 
document (including the date), and the form signed, before the participant undergoes any study -specific procedures. The rights and welfare of the participants will be protected by 
[CONTACT_183791] e to participate in this study.  
  
10.1.2  S
TUDY DISCONTINUATION AND CLOSURE  
 This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause.  Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_183792], and 
funding agency.   If the study is prematurely terminated or suspended, the  Principal Investigator 
(PI) will promptly inform study participants, the Instituti onal Review Board ( IRB), and sponsor 
and will provid e the reason(s) for the termination or suspension.  Study participants will be 
contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed , and satisfy the sponsor, IRB and/or Food and Drug Administration ( FDA). 
 
10.1.[ADDRESS_216994] by [CONTACT_3486], their staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover 
testing of biological sam ples and genetic tests in addition to the clinical information relating to 
participants.  Therefore, the study protocol, documentation, data, and all other information 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_216995] ( IRB), regulatory agencies or pharmaceutical company supplying study product 
may inspect all documents and records required to be maintained by [CONTACT_31691], including 
but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements.  
 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored with MICHR’s REDCap Service   
(https://www.michr.umich.edu/redcap-access) . This will not include the participant’s co ntact 
or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_183793]’s REDCap  Service  research staff will 
be secured and password protected. At the end of the study, all study databases will be de -
identified and archived at the NIMH database.  
 
10.1.4  FU
TURE USE OF STORED SPECIMENS AND DATA  
 
Data collected for this study will be analyzed and stored with  MICHR’s  REDCap  Service . After 
the study is completed, the de -identified, archived data will be transmitted to and stored at the 
NIMH data repository  for use by [CONTACT_21227]. 
Permission to transmit d ata to the NIMH data repository  will be inc luded in the informed 
consent.  
 
10.1.[ADDRESS_216996] Bldg 400  
Ann Arbor, MI [ZIP_CODE]  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   41 [PHONE_3943]  [PHONE_3944]  
[EMAIL_3605]  [EMAIL_3606]  
 
   
10.1.[ADDRESS_216997] 
semiannually to assess safety and efficacy data on each arm of the study. The  ISM will operate 
under the rules of an approved charter that will be written and reviewed at the organizational meeting of the ISM. At this time, each data element that the ISM  needs to assess will be clearly 
defined. The ISM will provide its input to NIMH.  
 
10.1.7  CL
INICAL MONITORING  
N/A 
 10.1.8  QUA
 LITY ASSURANCE AND QUALITY CONTROL  
N/A 
 10.1.[ADDRESS_216998]  KEEPI[INVESTIGATOR_1645]   
 [IP_ADDRESS] D
 ATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site i nvestigator . The investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  All data will be captured by [CONTACT_183794], a 21 CFR Par 11 -compliant system,  and automatically saved on the previously identified 
encrypted servers. Data include audiograms, TFI, THI, use/compliance monitoring,  etc. All data 
will be centrally collected, stored on an ongoing basis.  
 
Hardcopi[INVESTIGATOR_183747].  Data recorded in the 
electronic case report form ( eCRF ) derived from source documents should be consistent with 
the data recorded on the source d ocuments . Source code, documentation, user manuals and 
monitoring analyses will be made available on  completion of system. Data collected by [CONTACT_183795], and accessible only to study investigators with 
appropriate passw ords. 
 
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   42 Clinical data (including a dverse events ( AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into MICHR REDCap , a [ADDRESS_216999] protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
 All data will be captured by [CONTACT_183796]. Data include audiograms, TFI, THI, use/compliance 
monitoring,  etc. All data will be centrally collected, stored on an  ongoing basis.  
 Source code, documentation, user manuals and monitoring analyses will be made available on completion.  
 Data collected by [CONTACT_183797], and accessible only to study investigators with appropriate passwor ds. 
 
 
 
[IP_ADDRESS] S TUDY RECORDS RETENTION  
 
All records and information collected as part of participation in this study will be kept for 7 years from the date the study is completed.   
 
10.1.10  PR
 OTOCOL DEVIATIONS  
The investigator is responsible for complying with the protocol and all appropriate regulations 
and guidelines governing global clinical research.  Additionally, he/she is responsible for 
ensuring that all participating staff members are adequately trained and competent to perform 
his/her assigned tasks.  
 
Modi fications to the study protocol will not be implemented by [CONTACT_23664].  However, the investigator may implement a deviation form, or a change of, the protocol to eliminate an immediate hazard(s)  to the trial 
subjects without prior IRB/sponsor approval/favorable opi[INVESTIGATOR_1649].  As soon as possible, the implemented deviation or change, the reasons for it and if appropriate the proposed protocol amendment should be submitted to the IRB/sponsor.  
 Deviation s from the protocol must be recorded and reported (per local IRBMED guidelines) by 
[CONTACT_093]. The circumstances, action taken and impact of major deviations on the trial must be communicated by [CONTACT_079] [INVESTIGATOR_183748].    
 
10.1.11  PU
 BLICATION AND DATA SHARING POLICY  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   43 This study will  be conducted in accordance with the following  publication and data sharing  
policies and regulations:  
 
National Institutes of Health ( N IH) Public Access Policy, which ensures that the public has access 
to the published results of NIH funded research. It requires scientists to submit final peer -
reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central  
upon a cceptance for publication.  
 
T
his study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission r ule. As such,  this trial will be  registered at ClinicalTrials.gov, and results 
information from this  trial will  be submitted to ClinicalTrials.gov.  In addition, every attempt will 
be made to publish results in peer -reviewed journals.  In addition, in accordance with the 
funding source, data will be shared on the NIMH Data Archive.  
 
 
10.1.[ADDRESS_217000] of this trial.  The study leadership in conjunction with the <specify NIH 
Institute or C enter  (IC)> has established policies and procedures for all study gro up members to 
disclose all conflicts of interest and will establish a mechanism for the management of all 
reported dualities of interest.  
 
Susan Shore and David Martel are inventors on U.S. patent no. 3A9242067 “Personalized 
auditory -somatosensory stimulation to treat tinnitus.” We have disclosed this conflict  to the 
UMMS Conflict of Interest Board (MEDCOI)  and will seek their review of decisions pertaining to 
the actua l or perceived con flicts.  
 
10.2 ADDITIONAL CONSIDERATIONS  
N/A 
   
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.[ADDRESS_217001]  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
MICHR  Michigan Institute for Clinical & Health Research  
MML  Minimum Masking Level  
NIH  National Institutes of Health  
NIMH  NIH National Institute of Mental Health  
OSH A Occupational Safety and Health Administration  
PI [INVESTIGATOR_183749] -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   45 10.4 PROTOCOL  AMENDMENT  HISTORY  
The table below is intended to capture changes of IRB- approved versions of the protocol, 
including a description of the change and rationale. A Summary of Changes table for the current 
amendment is located in the Protocol Title Page.  
 
Version  Date  Description of Change  Brief Rationale  
1.2 11/6/[ADDRESS_217002]  “must have no 
greater than a mild hearing loss 
125-6000 Hz ”.  This is so we are able to  have 
similar hearing profiles from Stage 1 of the clinical trial.  
1.3 12/3/2018  Remove TinnTester from the 
screening appointment . The TinnTester is not needed 
to determine  eligibility.  
1.3 12/3/[ADDRESS_217003] of the 
device on the somatosensory system.  
1.3 12/3/2018  Remove Auditory Brainstem 
Response (ABR) from study.  Not completing this measure 
because it is not a primary 
objective for study aim .  
1.3 12/3/2018  Remove Residual Inhibition (RI) 
from study.  Not completing this measure 
because it is not a primary 
objective for study aim .  
1.4 1/29/2019  On page 40, deleted “Medical” 
and inserted “Independent 
Study”.  The monitor is not a medical 
monitor.  
1.5  3/29/2019  On page 4, added “central 
nervous system stimulants” and “benzodiazepi[INVESTIGATOR_1651]” to the 
medication exclusion criteria.  These drugs may be causing, 
contributing to, and influencing one’s tinnitus.  
1.5 3/29/ 2019  On page 2,  7, and 18,  changed 
“100” people consented to “200” 
people consented.  We need to expand this 
number in order to reach 50 
people enrolled in the study.  
1.6 1/27/[ADDRESS_217004] 
occurrences in the trial and changes on the consent form.  
1.6 1/27/2020  On pages 2, 7, and 18, updated 
the total number of participants 
from N=200 to N=300 To allow more screenings in 
order to reach goal of 50 
subjects actively enrolled.  
1.11 4/14/21  On pages 2, 7, and 18, updated the 
total number of participants from 
N=300 to N=400  To allow more screenings in 
order to reach goal of 50 
subjects with com plete data  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   46 1.11  4/14/21  On pages 2, 18, changed 50 
randomized subjects to up to 100 
randomized subjects  To allow more subjects to 
reach goal of 50 subjects 
with complete data  
7.1, 8.2 6/22/2021  Pg 24,  29, Clarifying exclusion 
criteria  Clarifying exclusion criteria 
with TFI and TT  
8.2 6/22/[ADDRESS_217005]. Stucken to refer as needed  
8.2 2/16/2022  Pg 29, changed adverse event 
reporting time from 7 days to 14 
days to match IRBMED  Changing adverse event 
reporting time to match 
IRBMED  
  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   47 11 REFERENCES  
Dobie, R. A. (1999). "A review of randomized clinical trials in tinnitus." Laryngoscope  109(8): 
1202 -1211.  
 O BJECTIVES: Review reports of randomized clinical trials (RCTs) in tinnitus to identify 
well- established treatments, promising developments, and opportunities for 
improvement in this area of clinical research. STUDY DESIGN: Literature review of RCTs 
(1964- 1998) identified by [CONTACT_183798]. 
METHODS: Studies were compared with the RCT criteria of Guyatt et al. for quality of design, performance, and analysis; "positive" results were critically examined for potential clinical relevance. RESULTS: Sixty -nine RCTs evaluated tocainide and related 
drugs, carbamazepi[INVESTIGATOR_050], benzodiazepi[INVESTIGATOR_1651], tricyclic antidepressants, 16 miscellaneous drugs, psychotherapy, electrical/magnetic stimulation, acupuncture, masking, 
biofeedback, hypnosis, and miscellaneous other nondrug  treatments. No treatment can 
yet be considered well established in terms of providing replicable long -term reduction 
of tinnitus impact, in excess of placebo effects. CONCLUSIONS: Nonspecific support and 
counseling are probably helpful, as are tricyclic antidepressants in severe cases. Benzodiazepi[INVESTIGATOR_1651], newer antidepressants, and electrical stimulation deserve further study. Future tinnitus therapeutic research should emphasize adequate sample size, open trials before RCTs, careful choice of outcome measures, and long -term follow -up. 
 
Marks, K. L., et al. (2018). "Auditory -s
 omatosensory bimodal stimulation desynchronizes brain 
circuitry to reduce tinnitus in guinea pi[INVESTIGATOR_43181]." Sci Transl Med  10(422).  
 The dorsal cochlear nucleus is the first site of multisensory convergence in mammalian 
auditory pathways. Principal output neurons, the fusiform cells, integrate auditory nerve inputs from the cochlea with somatosensory inputs from the head and neck. In previous work, we developed a guinea pig model of tin nitus induced by [CONTACT_183799] -unit synchrony, which are physiological correlates of tinnitus. We delivered 
repeated bimodal auditory -somatosensory stimulation to the dorsal cochlear nucleus of 
guinea pi[INVESTIGATOR_183750], choosing a stimulus interval known to induce long -term 
depression (LTD). Twenty minutes per day of LTD -inducing bimodal (but not unimodal) 
stimulation reduced physiological and behavioral  evidence of tinnitus in the guinea pi[INVESTIGATOR_183751] 25 days. Next, we applied the same bimodal treatment to 20 human subjects with 
tinnitus using a double -blinded, sham- controlled, crossover study. Twenty -eight days of 
LTD- inducing bimodal stimulation reduced tinnitus loudness and intrusiveness. 
Unimodal auditory stimulation did not deliver either benefit. Bimodal auditory -
somatosensory stimulation that induces LTD in the dorsal cochlear nucleus may hold promise for suppressing chronic tinnitus, which reduces quality of life for millions of tinnitus sufferers worldwide.  
Targeted auditory -somatosensory tinnitus treatment  Version 1.12 
Protocol HUM00143675 2/16/2022 
NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017   48  
 